- Home
- DOUG vs MOLN Comparison
DOUG vs MOLN Comparison
Compare DOUG & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DOUG | MOLN |
|---|---|---|
| Founded | 1911 | 2004 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Building operators | |
| Sector | Real Estate | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 178.2M | 170.5M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | DOUG | MOLN |
|---|---|---|
| Price | $1.81 | $4.35 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.38 |
| AVG Volume (30 Days) | ★ 409.6K | 972.0 |
| Earning Date | 05-05-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 118.68 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $955,578,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $374.07 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.53 | $3.53 |
| 52 Week High | $3.19 | $5.36 |
Technical Indicators
Market Signals| Indicator | DOUG | MOLN |
|---|---|---|
| Relative Strength Index (RSI) | 45.95 | 53.74 |
| Support Level | $1.68 | $4.13 |
| Resistance Level | $1.84 | $4.51 |
| Average True Range (ATR) | 0.07 | 0.07 |
| MACD | -0.02 | -0.02 |
| Stochastic Oscillator | 21.43 | 46.67 |
Price Performance
Historical ComparisonAbout DOUG Douglas Elliman Inc.
Douglas Elliman Inc is engaged in the real estate services business and seeks to acquire or invest in additional real estate services businesses. The Company also offers, through its subsidiaries and ventures, development marketing services and ancillary services, including mortgage, title, and escrow services. It generates revenue from commissions and other brokerage income, property management, and other ancillary services.
About MOLN Molecular Partners AG
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company is currently focusing on oncology through their robust pipeline of clinical and preclinical programs, with particular attention to MP0712, the key Radio-DARPin candidate targeting DLL3 now in a Phase 1/2a trial in the United States.